2015

Progress and Controversies in Gynecologic Oncology Conference

16-17 January 2015
Crowne Plaza Barcelona Fira Center
Barcelona, Spain

www.prIMEoncology.org/gyncongress2015
Welcome

On behalf of the Co-Chairs and Scientific Committee, we are pleased to invite you to the 2015 Progress and Controversies in Gynecologic Oncology Conference, to be held in Barcelona, Spain, on 16-17 January 2015.

This meeting will serve as a valuable forum for the presentation and discussion of newly available data across various gynecologic malignancies including ovarian, cervical, and endometrial cancers. Participants will be provided with updates on practice-changing data in a practical and interactive format, fostering discussion, and impacting clinical outcomes for patients.

Who Should Attend

The 2015 Progress and Controversies in Gynecology Oncology Conference is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners including allied health professionals, involved in the management of gynecologic malignancies.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

- Develop a practical approach to cervical cancer and vulvar cancer disease management
- Discuss the role of radiotherapy and systemic therapies in the management of endometrial cancer
- Derive the optimal management of ovarian cancer in the first-line setting based on disease stage and clinical presentation
- Assess standard and emerging therapeutic options for recurrent ovarian cancer and discuss their impact on patient outcomes

Continuing education

An application has been made to the EACCME® for CME Accreditation of this event.

Provider

This educational activity is provided by prIME Oncology.

Venue

Crowne Plaza Barcelona Fira Center
Avda Rius I Taulet, 1-3
Barcelona, Spain

Co-Chairs

Andreas du Bois, MD, PhD
Klinikum Essen Mitte
Essen, Germany

Stanley B. Kaye, MD
The Royal Marsden Hospital
Sutton, United Kingdom

Ignace Vergote, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Scientific Committee

Nicoletta Colombo, MD
University of Milan-Bicocca
Milan, Italy

Bradley J. Monk, MD, FACS, FACOG
Creighton University School of Medicine at St Joseph's Hospital and Medical Center
Phoenix, Arizona, United States

Andrés Poveda, MD
Fundación Instituto Valenciano de Oncología
Valencia, Spain

Eric Pujade-Lauraine, MD, PhD
Centre Hospitalier Universitaire Hôtel-Dieu
Paris, France

Continuing education

An application has been made to the EACCME® for CME Accreditation of this event.

Provider

This educational activity is provided by prIME Oncology.

All inquiries related to the 2015 Progress and Controversies in Gynecologic Oncology Conference may be addressed to: gyncongress2015@prIMEoncology.org
### Faculty

- Frédéric Amant, MD, PhD  
  Catholic University  
  Leuven, Belgium
- Michael Birrer, MD, PhD  
  Massachusetts General Hospital  
  Boston, Massachusetts, United States
- Anna Fagotti, MD, PhD  
  Catholic University of the Sacred Heart  
  Rome, Italy
- Philipp Harter, MD  
  Klinikum Essen Mitte  
  Essen, Germany
- Felix Hilpert, MD, DMSci  
  Christian-Albrechts-University of Kiel  
  Kiel, Germany
- Sven Mahner, MD, PhD  
  University Medical Center Hamburg-Eppendorf  
  Hamburg, Germany
- Mansoor Mirza, MD  
  Rigshospitalet  
  Copenhagen, Denmark
- Philippe Morice, MD  
  Institute Gustave Roussy  
  Villejuif, France
- Jan Persson, MD, PhD  
  Lund University  
  Lund, Sweden
- Jaime Prat, MD, PhD, FRCP  
  Hospital de la Santa Creu i Sant Pau  
  Barcelona, Spain
- Alexandra Taylor, MBBS, MD  
  The Royal Marsden Hospital  
  London, United Kingdom
- Vincent Vandecaveye, MD, PhD  
  University of Leuven  
  Leuven, Belgium

### Accommodation

A limited number of rooms are available at the Crowne Plaza Barcelona Fira Center (meeting venue). Delegates are recommended to make their hotel reservation as early as possible. You can book your hotel room with the online registration form at the registration tab at [www.prIMEoncology.org/gyncongress2015](http://www.prIMEoncology.org/gyncongress2015) or send an email to registrations.gyn@prIMEoncology.org.

Complete congress information and registration available at: [www.prIMEoncology.org/gyncongress2015](http://www.prIMEoncology.org/gyncongress2015)
Friday, 16 January 2015

13.00 Welcome and introduction

Session I Cervical Cancer and Vulvar Cancer
13.10 Current status of treatment for vulvar cancer  
Sven Mahner, MD, PhD
13.40 Technical innovations in robotic surgery  
Jan Persson, MD, PhD
14.10 Update on neoadjuvant chemotherapy in cervical cancer  
Nicoletta Colombo, MD
14.40 Update on targeted therapy and immunotherapy for cervical cancer  
Bradley J. Monk, MD, FACS, FACOG
15.10 Break

Session II Endometrial Cancer and Beyond
15.40 Debate: Role of radiotherapy in grade 3 FIGO IB endometrial cancer  
Pro Radiotherapy: Alexandra Taylor, MBBS, MD  
Contra Radiotherapy: Mansoor Mirza, MD
16.30 Treatment of recurrent endometrial cancer and evaluation of new agents  
Andrés Poveda, MD
17.00 What are the oncologic risks of morcellation of the uterus?  
Frédéric Amant, MD, PhD
17.30 Concluding remarks: Day 1
17.35 Adjourn

18.15 - 19.30 Industry-supported satellite symposium

Saturday, 17 January 2015

8.30 Welcome and introduction

Session III Ovarian Neoplasm I: Emerging Concepts
8.35 The impact of molecular testing on therapeutic decisions in ovarian cancer  
Michael Birrer, MD, PhD
9.05 Evolving role of upfront and postoperative imaging in ovarian cancer  
Vincent Vandecaveye, MD, PhD
9.35 Future of targeted agents and combinations in ovarian cancer  
Stanley B. Kaye, MD
10.05 Break

Session IV Ovarian Neoplasm II: Practical Applications in the First-Line Setting
10.40 Personalized medicine: Identification and treatment of fragile patients  
Felix Hilpert, MD, DMSci
11.10 Debate: HIPEC plays a role in treatment of advanced ovarian cancer  
Pro: Anna Fagotti, MD, PhD; Contra: Philipp Harter, MD
11.50 Break
12.15- 12.30 Industry-supported satellite symposium

Session V Borderline Ovarian Tumors
13.45 Pathologist’s view on the current status of borderline tumors  
Jaime Prat, MD, PhD, FRCPath
14.15 Clinical aspects: Fertility-sparing surgery of borderline ovarian tumors  
Philippe Morice, MD
14.45 Break

Session VI Ovarian Neoplasm III: Recurrence
15.00 Interactive Clinical Case: Platinum-resistant disease  
Ignace Vergote, MD, PhD
15.30 Interactive Clinical Case: Platinum-sensitive disease  
Andreas du Bois, MD, PhD
16.00 Ovarian cancer patients who have received multiple prior therapies: When to stop or continue treatment?  
Eric Pujade-Lauraine, MD, PhD
16.30 Concluding remarks: Day 2
16.45 Adjourn
Support

This educational activity is supported by AstraZeneca and F. Hoffmann-La Roche Ltd.

* Friday’s satellite symposium is supported by AstraZeneca
* Saturday’s satellite symposium is supported by F. Hoffmann-La Roche Ltd

Additional information and registration available at:
www.prIMEoncology.org/gyncongress2015